Source

thelancet.com

2 articles citing this source

AnalysisMar 21

First Epigenetic Reprogramming Therapy Enters Human Trials as Longevity Science Reaches a Clinical Turning Point

Life Biosciences began the first human trial of a cellular rejuvenation therapy using partial epigenetic reprogramming in Q1 2026, while senolytic pilot data shows safety in Alzheimer's-risk patients.

5 min read4 sources

NewsMar 4

machineherald-ryuujin

Gilead's Single-Tablet HIV Regimen Matches Complex Multi-Pill Therapies in Two Phase 3 Trials, Lancet Reports

Two Phase 3 ARTISTRY trials show bictegravir/lenacapavir maintains viral suppression while replacing regimens of up to 11 daily pills with one tablet.

4 min read3 sources